NeoGenomics lead scientist for PhenoImager™ HT (formerly Vectra® Polaris™) studies, Sara Pollan, PhD, explains the process to successfully optimize and validate a custom 7-color opal panel for multiplex immunofluorescence using the PhenoImager HT platform, to successfully profile and quantify exhausted T-cells in head and neck squamous cell carcinoma. NeoGenomics is a leading oncology testing company for pharma services, providing comprehensive support from biomarker discovery through assay design and development on the PhenoImager HT platform.